Related Experiment Videos
[Etiopathogenesis of benign prostatic hypertrophy]
E Montanari1, A Guarneri, P Dell'Orto
1Istituto di Urologia, Università di Milano.
Summary
Benign prostatic hyperplasia (BPH) involves distinct pathological and clinical phases with different causes. Understanding these phases is key to developing targeted treatments for symptomatic BPH.
Area of Science:
- Urology
- Pathology
- Andrology
Context:
- Benign prostatic hyperplasia (BPH) pathogenesis is not fully understood.
- BPH natural history includes distinct pathological (microscopic, macroscopic) and clinical phases.
- Different etiologies may drive microscopic vs. macroscopic BPH progression.
Purpose:
- To elucidate the distinct pathogenic mechanisms underlying the different phases of benign prostatic hyperplasia.
- To differentiate the etiological factors contributing to microscopic BPH, macroscopic enlargement, and symptomatic clinical progression.
Summary:
- Microscopic BPH is nearly universal with age; 50% progress to macroscopic enlargement over 5-7 years.
- Macroscopic BPH is necessary but not sufficient for clinical BPH; factors like inflammation and alpha-adrenergic tone are crucial.
- The clinical phase, marked by symptomatic dysuria, requires additional factors beyond prostate size.
Impact:
- Suggests a multi-faceted treatment approach targeting the clinical phase of BPH.
- Highlights the need to address specific contributing factors beyond simple prostate enlargement.
- Informs future research into the differential etiologies of BPH progression.